This website is intended for US healthcare professionals only.
VYEPTI permanent J-code (J3032) is now available. Learn more
Interested in discussing VYEPTI with a sales representative in your area? Request a meeting now.
VYEPTI CONNECT Liaisons are available to help you with access and reimbursement support and more, by phone.
Phone number: 833-4-VYEPTI (833-489-3784)
Available Monday through Friday, 8 am-8 pm (ET)
Fax number: 866-868-7071
For general VYEPTI product support, please call
833-4-VYEPTI (833-489-3784).
Want to keep up with the latest news and updates about migraine prevention with VYEPTI?
Discover the patient resources we have to support your patients along their VYEPTI treatment journey.
To report suspected adverse reactions, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.